Dupilumab and Infection Risk in Eczema: Overall Rates and Specific Infections Are Different Questions
DOCTOR’S NOTES · ECZEMA EVIDENCE
“Does this medicine weaken immunity?” is a reasonable question, but infection risk is not one interchangeable outcome. A common respiratory infection, an oral cold sore and a serious skin infection are different events. Dupilumab research in atopic dermatitis illustrates why looking at the categories is more informative than assigning every systemic medicine the same risk.
What seven adult trials showed
A 2019 pooled analysis included 2,932 adults with moderate-to-severe atopic dermatitis from seven placebo-controlled trials: 1,091 received placebo and 1,841 received one of the studied dupilumab regimens. Overall infection rates were similar. Serious or severe infections were less frequent with dupilumab in the exposure-adjusted comparison, with a risk ratio of 0.43 and 95% confidence interval of 0.22–0.85.
Herpesvirus infections overall were slightly more frequent, largely oral herpes, while clinically important herpes infections such as eczema herpeticum and shingles were less frequent in the pooled comparison. These categories should not be collapsed into “all herpes went up” or “no herpes risk.” The full analysis also makes clear that the participants were adults, not an infant safety population.
Understand exposure-adjusted results
People in pooled trials may have different lengths of observation. Exposure-adjusted analyses account for time under observation instead of simply dividing every event count by the number randomized. A reported rate per patient-year is not automatically the percentage of patients who experienced an infection. Likewise, a relative ratio does not tell an individual how many infections they will have next year.
| Outcome | What the adult analysis supports | What it does not promise |
|---|---|---|
| Overall infections | No overall increase detected versus placebo | Immunity to common infections |
| Serious/severe infections | A lower rate in the pooled comparison | That a serious infection cannot occur |
| Herpes-related outcomes | Different findings for oral herpes and more serious categories | That every herpes diagnosis has the same meaning |
Later safety follow-up adds context, not certainty
A 2025 safety analysis summarized more than 7,000 patient-years across trials and open-label extensions in several age groups. It reported no increase in overall, serious or severe infections with dupilumab in the analyzed program. Open-label extension findings remain subject to selection and lack of a continuing placebo comparison; they should not be read as randomized proof covering every future year or patient.
Different safety studies answer different questions, and the clinical program does not test every combination of medicines or health conditions. Share the full medication list and infection history with the prescriber. A conclusion about dupilumab should not be transferred to another biologic, an oral JAK inhibitor or a cosmetic moisturizer.
Do not use reassuring averages to dismiss symptoms
The current label has specific helminth-infection and vaccination precautions. These remain relevant even when an overall pooled infection result is reassuring. Tell the treating team about suspected infection and ask how it affects the individual treatment plan rather than deciding independently to continue, stop or add medication.
A rapidly changing painful or blistering eruption, fever or significant illness needs prompt assessment. Our eczema herpeticum guide discusses a particular warning pattern, and the article on crusty eczema and antibiotics explains why every weeping patch does not automatically call for an antibiotic.
Keep the treatment goal and safety plan together
At a review, ask how the clinician is balancing eczema control with personal infection risks, what symptoms require urgent contact and which routine precautions still apply. Better disease control and ongoing infection vigilance can coexist. Neither a favorable trial average nor a product's commercial description replaces the plan for a new illness.
Where everyday moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration and moisture-barrier support. It does not treat, cure or prevent eczema and was not the intervention in the medical studies above. Follow the product label and your clinician’s instructions for how moisturizer fits alongside prescribed care.
For a specific labeling question, read the live-vaccine evidence discussion. The mycophenolate safety guide concerns another drug and reinforces why one medicine’s infection findings cannot stand in for another’s.
Sources and research
- 2019 pooled analysis of seven adult randomized trials
- Full pooled analysis: endpoints and limitations
- 2025 safety analysis across age groups and longer follow-up
- Current Dupixent prescribing information
Prepared by the Dr. Arsy editorial team. Sources checked November 8, 2026. Educational content does not diagnose an individual or imply independent clinician review. The cited researchers and institutions do not endorse #003. Image is an AI-created product illustration, not a patient image or clinical result.